---
title: "Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Specific populations questions"
description: "Specific populations questions on Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Ibrance safety in men similar to that in women? Is Ibrance safe and effective for patients 65 and older? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Specific populations questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)

Specific populations questions that apply to every indication of Ibrance are on [Ibrance (palbociclib), all indications: Specific populations](https://www.evicenter.com/medical-information/ibrance/specific-populations).

## Specific populations

<a id="ibrance-men-safety"></a>

### Is Ibrance safety in men similar to that in women?

> “Male Patients with HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
>
> Based on limited data from postmarketing reports and electronic health records, the safety profile for men treated with IBRANCE is consistent with the safety profile in women treated with IBRANCE.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Male%20Patients%20with%20HR%2DPositive%2C%20HER2%2DNegative,in%20women%20treated%20with%20IBRANCE.)

<a id="ibrance-older-adults"></a>

### Is Ibrance safe and effective for patients 65 and older?

> “Of 444 patients who received IBRANCE in PALOMA-2, 181 patients (41%) were ≥65 years of age and 48 patients (11%) were ≥75 years of age. Of 347 patients who received IBRANCE in PALOMA-3, 86 patients (25%) were ≥65 years of age and 27 patients (8%) were ≥75 years of age.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Of%20444%20patients%20who%20received,%288%25%29%20were%20%E2%89%A575%20years%20of%20age.)

> “No clinically significant differences in safety or effectiveness of IBRANCE were observed between patients 65 years of age and older and younger adult patients.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=No%20clinically%20significant%20differences%20in,older%20and%20younger%20adult%20patients.)

Note: In the label, this sentence follows the age counts for PALOMA-2, PALOMA-3, and PATINA.

## Related pages
- [Medical information: Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
